Abstract 1026: Systemic Chemokines Levels and Incident Coronary Heart Disease and Ischemic Stroke Events in Asymptomatic Middle-aged Men: The Prime Study
Objectives: Circulating chemokines have been implicated in the pathogenesis of cardiovascular disease. We therefore examined the association of systemic levels of chemokines monocyte chemoattractant protein-1 (MCP-1), interferon-γ-inducible protein-10 (IP-10), CC chemokine ligand-5 (CCL5/RANTES) and eotaxin with incident coronary heart disease (CHD) and ischemic stroke events.
Methods: In the PRIME Study, a prospective cohort of 9711 healthy middle-aged men, the baseline plasma levels of MCP-1, IP-10, RANTES and eotaxin were measured in 621 men with incident CHD and 95 men with incident ischemic stroke events over 10 years of follow up, and in respectively 1242 and 190 age and study centres matched controls who were free of CHD and ischemic stroke at the time of the index date (nested case control study design). The standardized hazard ratios (HRs) of each chemokine (log-transformed) for CHD and ischemic stroke were estimated by conditional logistic regression.
Results: The association of IP-10 (HR=1.50; 95%CI: 1.09 to 2.07), RANTES (1.57; 1.07 to 2.31) and eotaxin levels (1.58; 1.09 to 2.28) with ischemic stroke was significant and was unaffected by adjustment for traditional cardiovascular risk factors and for hs-CRP. The association of RANTES (1.15; 1.01 to 1.32) and of eotaxin (1.15;1.02 to 1.30) with CHD disappeared after adjustment for risk factors, and especially for hypertension for RANTES and hs-CRP for eotaxin. MCP-1 level was unrelated to both arterial risks.
Conclusions: In healthy middle-aged men, higher systemic levels of IP-10, RANTES and eotaxin are more likely independent predictors of future ischemic stroke than CHD events.